Who we are
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel immunotherapeutics that guide T cells to overcome chronic infectious diseases and autoimmunity.
Barinthus Bio arose from the merger of Oxford University spinout Vaccitech, Plc and National Institutes of Health (NIH) and Johns Hopkins University spinout, Avidea Technologies, Inc. in 2021. Joining two leading immunotherapeutics companies with complementary technologies and expertise has created powerful synergies, fueling innovation and a focused pipeline of promising product candidates.
The foundation of Barinthus Bio is an experienced management team covering all stages of immunotherapeutics research and development from discovery through late stages of clinical development. Our team is unified by our values and driven by our mission of developing immunotherapies to improve the lives of patients.
The company’s headquarters are located in the UK with office and research facilities in the US.
Minimum 15 minutes delayed. Source: LSEG